Advances in Interstitial Lung Diseases: From Diagnosis to Treatment

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Pulmonology".

Deadline for manuscript submissions: 15 November 2025 | Viewed by 903

Special Issue Editors


E-Mail Website
Guest Editor
Interstitial Lung Disease Unit, Respiratory Department, Hospital Clinic de Barcelona (Barcelona), 08036 Barcelona, Spain
Interests: sarcoidosis; IPF—idiopathic pulmonary fibrosis; ILD—interstitial lung diseases; pulmonary fibrosis; pulmonology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor Assistant
Interstitial Lung Disease Unit, Respiratory Department, Hospital General de Granollers, 08402 Barcelona, Spain
Interests: IPF—idiopathic pulmonary fibrosis; ILD—interstitial lung diseases; pulmonary fibrosis; pulmonology; sleep

Special Issue Information

Dear Colleagues,

Interstitial lung diseases (ILDs) represent a diverse and complex group of disorders characterized by varying degrees of inflammation and fibrosis. Over the past decades, advances in imaging, molecular biology, and pharmacology have significantly improved our understanding of ILDs. Despite these developments, early diagnosis remains a challenge, and the therapeutic landscape continues to evolve with new antifibrotic agents, immunomodulatory treatments, and emerging precision medicine approaches. Additionally, the integration of holistic and comprehensive management strategies, including pulmonary rehabilitation, psychological support, and palliative care, is crucial for improving patient outcomes and the quality of life.

This Special Issue aims to provide an updated and multidisciplinary perspective on ILDs, covering state-of-the-art diagnostic methods, novel therapeutic strategies, and the role of personalized medicine. We seek to explore the impact of telemedicine in ILD management, particularly its potential for remote monitoring, early exacerbation detection, and expanded access to specialized care.

We invite researchers and clinicians to submit original research reports on novel treatment strategies and advances in decision making, and comprehensive reviews covering the following areas:

  • Advancements in ILD diagnosis, including high-resolution computed tomography (HRCT), artificial intelligence, and biomarker discovery.
  • Novel therapeutic approaches, such as antifibrotics, biologics, and combination therapies.
  • Holistic and multidisciplinary management strategies, including nursing care, pulmonary rehabilitation, psychological support, and patient-centered care.
  • The role of telemedicine and digital health solutions in ILD monitoring and treatment.

By bringing together the latest advances in ILD diagnosis, treatment, and management, this Special Issue aims to highlight emerging technologies, innovative therapies, and integrated care models that can improve early detection, slow disease progression, and enhance the overall management of ILD patients.

You may choose our Joint Special Issue in Journal of Respiration.

Dr. Jacobo Sellarés
Guest Editor

Dr. Jaume Bordas-Martinez
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • interstitial lung diseases (ILD)
  • pulmonary fibrosis
  • early diagnosis
  • biomarkers
  • antifibrotic therapy
  • immunomodulation
  • precision medicine
  • telemedicine
  • holistic care
  • patient-centered care

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 284 KB  
Article
A Pragmatic Tele-Nursing Program Improves Satisfaction of Patients with Pulmonary Fibrosis and Their Caregivers—A Pilot Study
by Mireia Baiges, David Iglesias, Sara Persentili, Marta Jiménez, Pilar Ortega and Jaume Bordas-Martinez
Medicina 2025, 61(8), 1385; https://doi.org/10.3390/medicina61081385 - 30 Jul 2025
Viewed by 608
Abstract
Background and Objectives: Specialized nurses play an essential role in managing pulmonary fibrosis. While tele-nursing has the potential to optimize disease management, current evidence regarding its impact remains limited. This study aimed to evaluate a tele-nursing intervention that provided unscheduled access to [...] Read more.
Background and Objectives: Specialized nurses play an essential role in managing pulmonary fibrosis. While tele-nursing has the potential to optimize disease management, current evidence regarding its impact remains limited. This study aimed to evaluate a tele-nursing intervention that provided unscheduled access to a specialized nurse via phone or email for both patients and caregivers. Materials and Methods: This was a prospective, single-center, open-label, and pre–post pilot study. Participants and their caregivers were provided with direct access to a specialized nurse, by phone and email, for unscheduled consultations. Patient-reported experience measures (PREMs) and patient-reported outcome measures (PROMs) were collected at baseline and after three months of tele-nursing access. PREMs were assessed using a 10-point Likert scale questionnaire, and PROMs were evaluated using the King’s Brief Interstitial Lung Disease (K-BILD) and the Living with Pulmonary Fibrosis (L-PF) questionnaires. Results: A total of 47 patients with pulmonary fibrosis receiving antifibrotic drugs were enrolled. At three months, 44 patients and 34 caregivers completed the questionnaires. Four patients did not complete the study due to death, lung transplantation, or transition to end-of-life care. No significant changes were observed in PROMs. However, PREMs showed significant improvements, with most scores exceeding 9/10. Patient satisfaction increased by 28% (p < 0.001), and caregiver satisfaction by 30% (p < 0.001). Caregivers of patients who did not complete the study also reported high satisfaction, comparable to that of other caregivers. Conclusions: A pragmatic and affordable tele-nursing program, based on direct phone and email consultations, may enhance patient and caregiver satisfaction in the management of pulmonary fibrosis. Full article
(This article belongs to the Special Issue Advances in Interstitial Lung Diseases: From Diagnosis to Treatment)
Back to TopTop